Current Report · Items 2.02, 9.01 · 8-K

Kura Oncology, Inc.

KURANASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 12, 2026Accepted Aug 12, 2026, 4:10 PM EDTCIK 1422143Accession 0001193125-26-346856

Company context

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Current securities

KURANASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 12, 2026, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Filed exhibits (1)

EX-99.1 (by filename) kura-ex99_1.htm

EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results - KOMZIFTI®(ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q - - KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch - - Long-term, frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM - - Clinical updates support darlifarnib’s potential to enhance targeted therapies in RCC and KRAS-mutated tumors - - $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments - - Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT - SAN DIEGO, August 12, 2026 - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported second quarter 2026 financial results and provided a corporate update. “In only its second full quarter of launch, KOMZIFTI established ear…

Open exhibit ↗

Free Registration